The coexistence of the BCR::ABL1 rearrangement and CALR mutation may change the clinical and laboratory manifestations of MPN and, for instance, in CML patients may be misinterpreted as failure of TKI therapy or disease transformation. This evidence concerns the gene ABL1 and myeloproliferative neoplasm.